免疫重建炎症综合征相关淋巴瘤：一项巴西回顾性队列研究。
Immune reconstitution inflammatory syndrome-associated lymphoma: A retrospective Brazilian cohort.
作者信息
Vargas Juliano Cordova, Cecyn Karin Zattar, de Oliveira Marques Mariana, Pereira Juliana, Tobias Braga Walter M, Hamerschlak Nelson, Tabacof Jacques, de Liz Caina D, Abdo André, Ferreira Paulo Roberto Abrão, Colleoni Gisele W Braga, Baiocchi Otavio C G
机构信息
Department of Clinical and Experimental Oncology Federal University of São Paulo São Paulo SP Brazil.
Department of Hematology Américas Oncologia e Hematologia São Paulo SP Brazil.
出版信息
EJHaem. 2023 Dec 20;5(1):147-152. doi: 10.1002/jha2.835. eCollection 2024 Feb.
After initiating combined antiretroviral therapy (cART), individuals with human immunodeficiency virus (HIV) may develop Hodgkin/non-Hodgkin lymphoma due to immune reconstitution inflammatory syndrome (IRIS). This retrospective cohort study evaluated the incidence, clinical features and prognosis of IRIS-associated lymphomas in Brazilian patients. Incidence in 2000-2019 was 9.8% (27/276 patients with HIV and lymphoma; viral load drop >1 log). Time between HIV diagnosis and cART initiation was <1 year in 70.3% of cases. Time between cART initiation and lymphoma diagnosis was <3 months in 11 cases and 3-6 months in 16 cases. Overall and progression-free survival rates were similar between cases of non-IRIS-associated lymphoma and IRIS-associated lymphoma.
开始联合抗逆转录病毒疗法（cART）后，感染人类免疫缺陷病毒（HIV）的个体可能因免疫重建炎症综合征（IRIS）而发生霍奇金/非霍奇金淋巴瘤。这项回顾性队列研究评估了巴西患者中与IRIS相关淋巴瘤的发病率、临床特征和预后。2000年至2019年的发病率为9.8%（276例HIV和淋巴瘤患者中有27例；病毒载量下降>1 log）。70.3%的病例中，HIV诊断与开始cART之间的时间<1年。开始cART与淋巴瘤诊断之间的时间，11例<3个月，16例为3至6个月。非IRIS相关淋巴瘤病例与IRIS相关淋巴瘤病例的总生存率和无进展生存率相似。
Zotero 插件